-
7/31/2019 Biomarcadores Que Incrementan Riesgo de Ictus en FA
1/12
Arrhythmia/Electrophysiology
Cardiac Biomarkers Are Associated With an Increased Riskof Stroke and Death in Patients With Atrial Fibrillation
A Randomized Evaluation of Long-Term Anticoagulation Therapy
(RE-LY) Substudy
Ziad Hijazi, MD; Jonas Oldgren, MD, PhD; Ulrika Andersson, MSc; Stuart J. Connolly, MD;Michael D. Ezekowitz, MB, ChB; Stefan H. Hohnloser, MD; Paul A. Reilly, PhD;
Dragos Vinereanu, MD, PhD; Agneta Siegbahn, MD, PhD;Salim Yusuf, MD, PhD; Lars Wallentin, MD, PhD
BackgroundCardiac biomarkers are strong predictors of adverse outcomes in several patient populations. We evaluated
the prevalence of elevated troponin I and N-terminal pro-B-type natriuretic peptide (NT-proBNP) and their association
to cardiovascular events in atrial fibrillation (AF) patients in the Randomized Evaluation of Long-Term Anticoagulation
Therapy (RE-LY) trial.
Methods and ResultsBiomarkers at randomization were analyzed in 6189 patients. Outcomes were evaluated by Coxproportional hazards models adjusting for established cardiovascular risk factors and the CHADS2 and CHA2DS2-VASc
risk scores. Patients were stratified based on troponin I concentrations: 0.010 g/L, n2663; 0.010 to 0.019 g/L,
n2006; 0.020 to 0.039 g/L, n1023;0.040 g/L, n497; and on NT-proBNP concentration quartiles: 387; 387
to 800; 801 to 1402; 1402 ng/L. Rates of stroke were independently related to levels of troponin I with 2.09%/year
in the highest and 0.84%/year in the lowest troponin I group (hazard ratio [HR], 1.99 [95% CI, 1.173.39]; P0.0040),
and to NT-proBNP with 2.30%/year versus 0.92% in the highest versus lowest NT-proBNP quartile groups, (HR, 2.40
[95% CI, 1.414.07]; P0.0014). Vascular mortality was also independently related to biomarker levels with
6.56%/year in the highest and 1.04%/year the lowest troponin I group (HR, 4.38 [95% CI, 3.056.29]; P0.0001),
and 5.00%/year in the highest and 0.61%/year in the lowest NT-proBNP quartile groups (HR, 6.73 [3.9511.49];
P0.0001). Biomarkers increased the C-statistic from 0.68 to 0.72, P0.0001, for a composite of thromboembolic
events.
ConclusionsElevations of troponin I and NT-proBNP are common in patients with AF and independently related to
increased risks of stroke and mortality. Cardiac biomarkers seem useful for improving risk prediction in AF beyond
currently used clinical variables.
Clinical Trial RegistrationURL: http://www.clinicaltrials.gov. Unique identifier: NCT00262600.
(Circulation. 2012;125:1605-1616.)
Key Words: atrial fibrillation cardiac biomarkers natriuretic peptide risk prediction troponin
The prevalence of atrial fibrillation (AF) is increasing andis projected to reach epidemic proportions in comingdecades.1 AF is associated with a 5-fold increase in the rate of
ischemic stroke and doubled total mortality.2 Strategies for
identifying patients at risk for thromboembolism are com-
monly based on clinical variables, eg, congestive heart
failure, hypertension, age, diabetes mellitus, and prior stroke
or transient ischemic attack (TIA) in the widely used
CHADS2 risk score.3 So far, no biochemical marker has been
shown to provide incremental information. Cardiac troponin,
an intracellular protein involved in heart muscle contraction,
is an established biochemical marker of myocardial cell
Received April 20, 2011; accepted February 16, 2012.From the Uppsala Clinical Research Center and Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden (Z.H., J.O., L.W.);
Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden (U.A.); Population Health Research Institute, Hamilton, Canada (S.J.C., S.Y.);Lankenau Institute for Medical Research and the Heart Center, Wynnewood, PA (M.D.E.); Department of Cardiology, J.W. Goethe University, Frankfurt,Germany (S.H.H.); Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT (P.A.R.); Department of Cardiology, University Hospital of Bucharest,
Bucharest, Romania (D.V.); and Uppsala Clinical Research Center and Department of Medical Sciences, Clinical Chemistry, Uppsala University,Uppsala, Sweden (A.S.).
The online-only Data Supplement is available with this article at http://circ.ahajournals.org/lookup/suppl/doi:10.1161/CIRCULATIONAHA.
111.038729/-/DC1.Correspondence to Ziad Hijazi, MD, Uppsala Clinical Research Center, Dag Hammarskjolds vag 14B, 1st floor, SE- 752 37 Uppsala, Sweden. E-mail
2012 American Heart Association, Inc.Circulation is available at http://circ.ahajournals.org DOI: 10.1161/CIRCULATIONAHA.111.038729
1605
http://www.clinicaltrials.gov/http://circ.ahajournals.org/lookup/suppl/doi:10.1161/CIRCULATIONAHA.111.038729/-/DC1http://circ.ahajournals.org/lookup/suppl/doi:10.1161/CIRCULATIONAHA.111.038729/-/DC1http://circ.ahajournals.org/lookup/suppl/doi:10.1161/CIRCULATIONAHA.111.038729/-/DC1http://circ.ahajournals.org/lookup/suppl/doi:10.1161/CIRCULATIONAHA.111.038729/-/DC1http://circ.ahajournals.org/lookup/suppl/doi:10.1161/CIRCULATIONAHA.111.038729/-/DC1http://www.clinicaltrials.gov/ -
7/31/2019 Biomarcadores Que Incrementan Riesgo de Ictus en FA
2/12
damage. B-type natriuretic peptide (BNP), a neurohormone
secreted from the cardiac ventricles, is a recognized marker of
myocardial wall tension, and its inactive part, N-terminal
fragment (N-terminal pro-B-type natriuretic peptide [NT-
proBNP]]), as well.4 Elevated levels of troponin and NT-
proBNP have repeatedly been demonstrated as important
markers of increased mortality and morbidity in acute coro-
nary syndromes,5,6 stable coronary artery disease,7,8, conges-
tive heart failure,9,10 and even in general community-based
populations.11,12 The prevalence and clinical significance of
elevated cardiac troponin I and NT-proBNP in nonvalvular
AF patients at risk for stroke is unknown.
Clinical Perspective on p 1616
The Randomized Evaluation of Long-Term Anticoagula-
tion Therapy (RE-LY) trial recently demonstrated the supe-
riority of dabigatran versus warfarin for stroke prevention in
18 113 AF patients.13 In this prospectively designed bio-
marker substudy, we investigated the prevalence of elevated
troponin I and NT-proBNP and their association to cardio-vascular events in a representative subgroup constituting
one-third of the RE-LY cohort.
Methods
Study Population and Trial DesignThe study organization, trial design, patient characteristics andoutcomes of the RE-LY study have been published previously.13 Inbrief, RE-LY was a prospective, multicenter, randomized trialcomparing 2 blinded doses of dabigatran with open-label warfarinfor a minimum of 12 months in 18 113 patients. Inclusion criteriawere documented AF and at least one of the following risk factors forstroke: previous stroke or TIA; congestive heart failure or reducedleft ventricular ejection fraction (40%); at least 75 years of age; or
at least 65 years of age with diabetes mellitus, hypertension, orcoronary artery disease. Exclusion criteria included severe heartvalve disorder, recent stroke, increased risk of hemorrhage, creati-nine clearance 30 mL/min, or active liver disease. The 6189 (of18113) patients in the present study represented 446 of 951 sites in38 of 44 countries in the RE-LY trial. The primary efficacy outcomein the study was fatal and nonfatal stroke (ischemic, hemorrhagic, orunspecified) or systemic embolism, and the secondary outcomeswere total mortality, vascular (including hemorrhagic) mortality,nonvascular mortality, and a composite thromboembolic end pointconsisting of ischemic stroke, systemic embolism, myocardial in-farction, pulmonary embolism, and vascular mortality (excludinghemorrhagic death). The primary safety outcome was major bleed-ing. Median follow-up was 2.0 years for the main trial and 2.2 yearsfor the substudy population. Outcomes were assessed by study visits
scheduled at 3-month intervals during the first year and 4-monthintervals thereafter. Each event was classified by 2 independentadjudicators from an international team, blinded to treatment assign-ments. Definition of the outcomes has been described previously.13
Blood SamplingVenous blood was drawn at randomization, before initiation of studytreatment, with the use of a 21/22 gauge needle into Vacutainer tubescontaining EDTA. The blood was centrifuged within 30 minutes at 2000g
for 10 minutes. The tubes were thereafter immediately frozen at 20 C orcolder. Aliquots were stored at 70C to allow batch analysis.
Laboratory MethodsAll plasma samples were centrally analyzed in Uppsala ClinicalResearch Center laboratory, Sweden. Troponin I was analyzed with
the Access AccuTnI assay (Beckman Coulter, Inc, Fullerton, CA), a2-site immunoenzymatic (sandwich) immunoassay. The lower limit
of detection with this assay is 0.006 g/L with 0.014 g/L as thelowest concentration measurable with a coefficient of variation of10% and 0.02 g/L as the 99th percentile upper reference limit(URL) for subjects aged 60 years14 and 0.04 g/L as the 99thpercentile URL regardless of age.15 With present instrument calibra-tion all troponin I concentrations 0.010 g/L are reported as0.010 g/L and considered undetectable; levels 0.010 are re-garded as detectable and reported with 2 significant figures; levels
0.020 g/L are considered elevated.NT-proBNP was analyzed by using the Sandwich Immunoassay,
Elecsys, Roche Diagnostics. The analytic range extends from 20 to35 000 ng/L according to the manufacturer. The upper referencelevel (97.5th percentile) in men and woman aged 40 to 65 years is184 and 268 ng/L, respectively, and age 66 to 76 years, 269 and 391ng/L, respectively.16 The lowest concentration measurable with acoefficient of variation 10% is 30 ng/L.17
Statistical AnalysisThe sample size for the substudy was prospectively estimated at5744 patients, based on an expected event rate of 1.6%/year(corresponding to a total event rate of 3.2%), and the assumptionsthat the biomarker was related to outcome in the following manner:the total event rate for the lower quartile is 1.6%, for the middle
quartiles 3.2%, and for the upper quartile 6.4%. A 2-sided test of thenull hypothesis of no difference in event rate between the lowerquartile and a middle quartile requires 1436 patients per group whenthe significance level is 5% and the power is 80%. The number ofsamples in total was thus calculated to 414365744, to account formissing information blood samples, was planned from 6200patients of the 18 113 patients in the RE-LY study. The final numberof samples in the present analysis was 6189, composed of 2561patients participating in a comprehensive RE-LY biomarker sub-study program and 3628 randomly selected patients with cardiacbiomarkers (troponin I and NT-proBNP) obtained at randomizationin the main RE-LY study.
Patients were grouped according to quartiles of NT-proBNP levels,387 ng/L (n1547), 387 to 800 ng/L (n1547), 801 to 1402 ng/L(n1544), and 1402 ng/L (n1551). Troponin I results were, as
expected, extremely skewed, and patients were in the present studygrouped according to cutoff levels based on results from previousstudies, instead of 4 equally sized groups. Troponin I levels wereundetectable (0.010 g/L) in 2663 (43.0%) patients, 2006 (32.4%)patients had detectable troponin I levels0.010 to 0.019 g/L, ie, up tothe 99th percentile for apparently healthy individuals 60 years age.18
One thousand twenty-three (16.5%) patients had slightly elevatedtroponin I levels 0.020 to 0.039 g/L, and 497 (8.0%) had clearlyelevated troponin I levels 0.040 g/L, ie, above the 99th percentileURL for the troponin I assay regardless of age.15
Demographics and baseline characteristics were summarized forthe troponin I and NT-proBNP level groups with the use offrequencies for categorical variables, and median and 25th and 75thquartiles for continuous variables. Because of the low numbers ofpatients in the CHADS2 scores, 0, 4, 5, and 6 patients were groupedin CHADS2 classes of 0 to 1, 2, and 3. For tests of differences
among groups, the 2 test was used for categorical variables, andKruskal-Wallis test was used for continuous variables.
The risk of event is reported as percentage per year, which wascalculated by dividing the total number of patients with events by thetotal number of patient-years of follow-up. Cumulative hazard plotswere used to illustrate the timing of events. The relations betweenlevels of troponin I and NT-proBNP at randomization and eventswere investigated by using Cox proportional hazards regression.Three different models were used. Model A was adjusted for studytreatment, use of (prestudy) anticoagulant treatment at randomizationand established risk factors for cardiovascular disease (age, sex, bodymass index, smoking status, sitting systolic blood pressure, sittingheart rate, AF duration, AF type, creatinine clearance, diabetes,coronary artery disease, previous stroke/systemic embolism/TIA,heart failure, hypertension, treatment at randomization with aspirin,
angiotensin-converting enzyme inhibitors or angiotensin II receptorblockers, and statins). Model B was only adjusted for study treatment
1606 Circulation April 3, 2012
-
7/31/2019 Biomarcadores Que Incrementan Riesgo de Ictus en FA
3/12
and the CHADS2 score (1 point for each of congestive heart failure,hypertension, age 75 years, diabetes mellitus, and 2 points forprevious stroke/TIA) by using 6 CHADS2 classes (CHADS2 score of5 and 6 combined). Model C was only adjusted for study treatmentand the CHA2DS2-VASc score (1 point for each of congestive heartfailure, hypertension, age 65 but 75 years, diabetes mellitus,prior stroke or TIA, vascular disease, and sex category; and 2 pointsfor each of age of75 years and prior stroke or TIA) by using 7
classes (scores of 0 and 1 combined, and scores of 7, 8, and 9combined). The 2 cardiac biomarkers were included separately and
jointly, as well, in the models. The results of hazard ratios for modelA are presented in Results and tables. Models B and C yieldedsimilar hazard ratios (see online-only Data Supplement Tables I andII). The effects of randomized treatment on outcome in relation tolevel of biomarker was evaluated with Cox proportional hazardsmodel with treatment group, biomarker, and their interaction asdependent variables. The proportional hazards assumption withrespect to the cardiac biomarkers was assessed by visual inspectionof log-cumulative hazard plots and by extending the Cox model witha time-by-biomarker interaction factor. In addition, sensitivity anal-yses using logistic regression were performed (results not shown).
The increased discriminative values of troponin I and NT-proBNPwere investigated by estimating the difference in C-statistics between
models with and without respective cardiac biomarker19
and also theintegrated discrimination improvement measure (IDI) as describedby Pencina et al.20 In these analyses, the occurrence/nonoccurrenceof stroke or systemic embolism and composite thromboembolicevents, respectively, during the follow-up period was used as abinary response, and the C value will be the same as the area underthe ROC curve. The relative IDI was calculated to facilitate inter-pretation of the IDI.21
A probability value of0.05 from 2-sided tests was considered toindicate statistical significance. The statistical software packageSAS, version 9.2 for Windows (SAS institute, Cary, NC) was usedfor all analyses.
Results
Baseline Characteristics in Relation to Levels of
Cardiac BiomarkersPatient characteristics are summarized in Table 1. Troponin I
levels ranged from 0.010 to 7.1 g/L, with a median of
0.011, 25th and 75th percentile values of0.010 and 0.019
g/L. Detectable levels of troponin I (0.010 g/L) were
found in 3526 (57.0%) and elevated levels of troponin I
(0.020 g/L) in 1520 (24.6%) patients (Table 1). Several
patient characteristics, eg, higher age, previous myocardial
infarction, history of congestive heart failure, AF rhythm at
randomization (at the time of blood sampling), and lower
creatinine clearance were significantly associated with higher
troponin I levels, all P0.0001 (Table 1).
NT-proBNP levels ranged from 5 to 44959 ng/L, with a
median of 801, 25th and 75th percentile values of 387 and 1403
ng/L. Several patient characteristics, most prominently age, AF
rhythm at randomization, history of congestive heart failure, and
lower creatinine clearance, were significantly associated with
higher NT-proBNP levels, all P0.0001 (Table 1).
The proportion of patients with CHADS2 risk scores 0 to 1
was highest (37.3% and 38.6%, respectively) in groups with
the lowest levels of cardiac biomarkers (troponin I 0.010
g/L and NT-proBNP 387 ng/L) and lowest (25.4% and
25.6%, respectively) in groups with the highest levels of
cardiac biomarkers (troponin I0.040 g/L and NT-proBNP
1402 ng/L, respectively). The opposite applied to the
proportion of patients with a CHADS2 scores
3, which waslowest (27.8% and 25.5%, respectively) in groups with
undetectable troponin I (0.010 g/L) and low NT-proBNP
387 ng/L, and highest (37.6% and 38.6%, respectively) in
the groups with highest troponin I (0.040) g/L and highest
NT-proBNP (1402 ng/L), respectively (Table 1).
Stroke or Systemic EmbolismDuring the median of 2.2 years follow-up, there were 183 events
of stroke or systemic embolism. The annual rates of stroke or
systemic embolism were lowest, 0.84%, in the group with
undetectable troponin I, in comparison with 2.09% (HR, 1.99;
95% CI, 1.173.39) in the highest troponin I group (P0.0040)
(Figure 1A, Table 2). In relation to NT-proBNP, the annual rates
of stroke or systemic embolism were lowest, 0.92%, in the
quartile group with low NT-proBNP, in comparison with 2.30%
(HR, 2.40; 95% CI, 1.414.07) in the highest NT-proBNP
(P0.0014) (Figure 1B, Table 2). The effects of troponin I
remained significant (P0.0232) after adjustment for NT-
proBNP in the multivariable model, and for NT-proBNP
(P0.0112) adjusted for troponin I, as well.
MortalityDuring the follow up 450 patients died, 297 of which died of
vascular causes. In the group with undetectable troponin I,
annual vascular death rate was 1.04% in comparison with
6.56% (HR, 4.38; 95% CI, 3.05 6.29) in the highest troponin
I group (P0.0001) (Figure 2A, Table 2). In relation to
NT-proBNP, the annual rates of vascular death were 0.61% in
the lowest NT-proBNP group, in comparison with 5.00%
(HR, 6.73; 95% CI, 3.9511.49) in the highest NT-proBNP
group (P0.0001) (Figure 2B, Table 2). The effects of
troponin I remained significant (P0.0001) after adding
NT-proBNP to the multivariable model, and for NT-proBNP
(P0.0001) adjusted for troponin I, as well.One hundred fifty-three patients died of nonvascular
causes. The rate of nonvascular mortality was higher among
patients with elevated troponin I levels, P0.0127, but
without a gradual increase by troponin I levels (Table 2).
There was no significant association between NT-proBNP
levels and nonvascular death.
Myocardial InfarctionThere were 103 myocardial infarctions during follow-up. The
annual rates were 0.49% in the group with undetectable
troponin I and 1.69% (HR 3.04; 95% CI 1.645.64) in the
highest troponin I group (P0.0052) (Table 2). The associ-
ation of troponin I and myocardial infarctions remained
significant after adding NT-proBNP to the model. There was
no significant relation between NT-proBNP levels and myo-
cardial infarctions.
Composite Thromboembolic End PointThere were 482 composite thromboembolic events (ischemic
stroke, systemic embolism, pulmonary embolism, myocardial
infarction, and vascular death excluding hemorrhagic death).
In the group with undetectable troponin, the annual rates of
the composite thromboembolic end point were 2.00% in
comparison with 8.85% (HR, 3.43; 95% CI, 2.574.56) in the
highest troponin I group (P0.0001) (Table 2). ConcerningNT-proBNP, the annual rates of the composite thromboem-
Hijazi et al Cardiac Biomarkers in Atrial Fibrillation 1607
-
7/31/2019 Biomarcadores Que Incrementan Riesgo de Ictus en FA
4/12
bolic end point were 1.78% in the lowest quartile group ofNT-proBNP, in comparison with 6.76% (HR, 3.55; 95% CI,
2.515.02) in the highest NT-proBNP group (P0.0001)
(Table 2). The effects of troponin I remained significant
(P0.0001) after adding NT-proBNP to the multivariable
model, and for NT-proBNP (P0.0001) adjusted for effects
of troponin I, as well.
Major BleedingThere were 334 major bleeds. In the group with undetectable
troponin I, the annual rate of major bleed was 1.72% in
comparison with 4.38% (HR, 2.01; 95% CI, 1.39 2.90) in the
highest troponin I group (P0.0009) (Table 2). There was no
significant association between NT-proBNP levels and majorbleeding.
Cardiac Biomarkers Levels in Relation toCHADS
2Score
Figure 3A illustrates the annual rates of the composite
thromboembolic end point according to troponin I levels and
CHADS2 score. The pattern of gradually higher rates of the
composite thromboembolic end point concomitant with
higher troponin I levels was consistent in all CHADS2 scores,
including the group with CHADS2 scores 0 to 1. The highest
annual rates of the composite end point, 11.4%, were found in
the group with CHADS2 3 and highest troponin I (0.040
g/L) compared with the lowest annual risk of 1.48%, in the
group with CHADS2 0 to 1 and undetectable troponin I
(0.010 g/L).
Annual rates of the composite thromboembolic end pointaccording to NT-proBNP levels and CHADS2 score are
Table 1. Baseline Characteristics According to Troponin I and NT-proBNP group
Groups All
Troponin I
0.010 g/L 0.010 0.019 g/L 0.0200.039 g/L 0.040 g/L P Value*
No. in substudy 6189 2663 2006 1023 497
Follow-up time, median (25th, 75th pct), y 2.20 (1.78, 2.52) 2.22 (1.88, 2.54) 2.25 (1.74, 2.56) 2.08 (1.67, 2.40) 2.10 (1.71, 2.46)
Region West EuropeNorth America 3512 (56.7) 1553 (58.3) 1175 (58.6) 529 (51.7) 255 (51.3)
Age, median (25th, 75th pct), y 72.0 (67.0, 77.0) 71.0 (66.0, 76.0) 73.0 (67.0, 78.0) 73.0 (67.0, 78.0) 72.0 (65.0, 78.0) 0.0001
Body mass index, median (25th, 75th pct), kg/m2 28.1 (25.3, 31.6) 28.2 (25.6, 31.8) 28.1 (25.2, 31.5) 28.0 (25.1, 31.9) 27.6 (24.8, 31.2) 0.0190
Male sex, n (%) 3944 (63.7) 1631 (61.2) 1288 (64.2) 685 (67.0) 340 (68.4) 0.0008
Current smoker, n (%) 483 (7.8) 202 (7.6) 157 (7.8) 79 (7.7) 45 (9.1) 0.7369
Systolic blood pressure, median (25th, 75th
pct), mm Hg
130.0 (120.0, 144.0) 130.0 (120.0, 142.0) 133.0 (120.0, 145.0) 130.0 (120.0, 145.0) 130.0 (120.0, 140.0) 0.0027
Heart rate median (25th, 75th pct) 72.0 (62.0, 82.0) 72.0 (63.0, 82.0) 72.0 (62.0, 82.0) 72.0 (63.0, 82.0) 72.0 (62.5, 81.0) 0.9794
AF rhythm at baseline (%) 4519 (73.2) 1867 (70.3) 1490 (74.5) 783 (76.8) 379 (76.4) 0.0001
Type of AF, n (%)
Paroxysmal 1848 (29.9) 871 (32.7) 580 (28.9) 259 (25.3) 138 (27.8) 0.0001
Persistent 1609 (26.0) 726 (27.3) 474 (23.6) 285 (27.9) 124 (24.9)
Permanent 2731 (44.1) 1066 (40.0) 951 (47.4) 479 (46.8) 235 (47.3)
AF duration, n (%)
3 mo 1794 (29.0) 756 (28.4) 562 (28.0) 316 (30.9) 160 (32.2) 0.2226
3 mo2 y 1441 (23.3) 646 (24.3) 461 (23.0) 220 (21.5) 114 (22.9)
2 y 2954 (47.7) 1261 (47.4) 983 (49.0) 487 (47.6) 223 (44.9)
Heart failure, n (%) 1859 (30.0) 618 (23.2) 588 (29.3) 436 (42.6) 217 (43.7) 0.0001
Hypertension, n (%) 4852 (78.4) 2112 (79.3) 1575 (78.5) 791 (77.3) 374 (75.3) 0.1773
Age 75 y, n (%) 2356 (38.1) 883 (33.2) 838 (41.8) 426 (41.6) 209 (42.1) 0.0001
Diabetes mellitus, n (%) 1322 (21.4) 519 (19.5) 447 (22.3) 239 (23.4) 117 (23.5) 0.0153
Previous stroke/TIA, n (%) 1216 (19.6) 538 (20.2) 387 (19.3) 183 (17.9) 108 (21.7) 0.2560
CHADS2 score, n (%)
01 2025 (32.7) 992 (37.3) 636 (31.7) 271 (26.5) 126 (25.4) 0.0001
2 2197 (35.5) 932 (35.0) 710 (35.4) 371 (36.3) 184 (37.0)
3 1967 (31.8) 739 (27.8) 660 (32.9) 381(37.2) 187 (37.6)
Prior myocardial infarction, n (%) 1078 (17.4) 330 (12.4) 375 (18.7) 241 (23.6) 132 (26.6) 0.0001
Coronary artery disease, n (%) 1540 (24.9) 578 (21.7) 516 (25.7) 293 (28.6) 153 (30.8) 0.0001
CrCL at baseline, mL/min (25th-75th pct) 69.0 (54.2, 87.1) 73.4 (58.1, 90.3) 68.1 (53.6, 85.4) 64.3 (50.1, 82.0) 63.1 (49.3, 81.1) 0.0001
Medications at baseline, n (%)
Aspirin 2214 (35.8) 900 (33.8) 722 (36.0) 394 (38.5) 198 (39.8) 0.0093
-blocker 4102 (66.3) 1762 (66.2) 1352 (67.4) 656 (64.1) 332 (66.8) 0.3445
ACE inhibitor and/or ARB 4313 (69.7) 1761 (66.1) 1447 (72.1) 737 (72.0) 368 (74.0) 0.0001
Statin 2670 (43.1) 1198 (45.0) 851(42.4) 409 (40.0) 212 (42.7) 0.0396
Amiodarone 700 (11.3) 296 (11.1) 214 (10.7) 118 (11.5) 72 (14.5) 0.1127
NT-proBNP indicates N-terminal pro-B-type natriuretic peptide; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CrCL, creatine clearance;
AF, atrial fibrillation; pct, percentile; and TIA, transient ischemic attack.
*The P value is based on Kruskal-Wallis test for continuous variables and the 2 test for categorical variables.
1608 Circulation April 3, 2012
-
7/31/2019 Biomarcadores Que Incrementan Riesgo de Ictus en FA
5/12
illustrated in Figure 3B. The general trend of increasing ratesof the composite thromboembolic end point with increasing
NT-proBNP levels was consistent in all CHADS2 scores,
including the group with CHADS2 scores 0 to 1. The
highest annual rate of the composite end point, 8.99%, was
found in the group with CHADS2 3 and highest NT-
proBNP (1402 ng/L) compared with the lowest yearly
risk of 1.55%, in the group with CHADS2 0 to 1 and lowest
NT-proBNP (387 ng/L).
Figure 3C illustrates the annual rates of the composite
thromboembolic end point in relation to cardiac biomarkers
only. The pattern of gradually higher rates of the composite
thromboembolic end point is apparent in all biomarkergroups, with the highest annual rate of the composite end
point, 12.0%, found in patients with highest levels of troponinI (0.040 g/L) in combination with highest levels of
NT-proBNP (1402 ng/L).
Study Treatment and SubgroupsFor all the above outcomes there were no significant interac-
tions between troponin I or NT-proBNP groups and effects of
study treatment with warfarin or dabigatran 110 mg or 150
mg. Exploratory analyses of relations between troponin or
NT-proBNP levels and outcomes within subgroups defined
by age (75; 75 years), sex, regions (North America and
Western Europe versus others, Asian versus non-Asian coun-
tries), CHADS2 score (01; 2; 36), prevalent coronaryartery disease versus no coronary artery disease, or prevalent
Table 1. Continued
NT-proBNP
387 ng/L 387 800 ng/L 8011402 ng/L 1402 ng/L P Value*
1547 1547 1544 1551
2.17 (1.78, 2.42) 2.23 (1.79, 2.54) 2.23 (1.84, 2.57) 2.19 (1.71, 2.50)
872 (56.4) 895 (57.9) 887 (57.4) 858 (55.3)
70.0 (65.0, 75.0) 71.0 (66.0, 76.0) 73.0 (67.0, 78.0) 74.0 (68.0, 79.0) 0.0001
28.6 (25.6, 32.0) 28.4 (25.7, 32.0) 27.9 (25.2, 31.6) 27.5 (24.7, 30.8) 0.0001
965 (62.4) 1056 (68.3) 977 (63.3) 946 (61.0) 0.0002
121 (7.8) 132 (8.5) 119 (7.7) 111 (7.2) 0.5589
134.0 (122.0, 145.0) 130.0 (120.0, 144.0) 131.0 (120.0, 144.0) 130.0 (120.0, 140.0) 0.0001
65.0 (60.0, 76.0) 73.0 (64.0, 82.0) 75.0 (65.0, 84.0) 75.0 (66.0, 86.0) 0.0001
502 (32.6) 1233 (80.0) 1379 (89.4) 1405 (90.8) 0.0001
955 (61.7) 373 (24.1) 257 (16.7) 263 (17.0) 0.0001
325 (21.0) 401 (25.9) 447 (29.0) 436 (28.1)
267 (17.3) 773 (50.0) 839 (54.4) 852 (54.9)
529 (34.2) 396 (25.6) 392 (25.4) 477 (30.8) 0.0001
393 (25.4) 331 (21.4) 349 (22.6) 368 (23.7)
625 (40.4) 820 (53.0) 803 (52.0) 706 (45.5)
292 (18.9) 422 (27.3) 473 (30.6) 672 (43.3) 0.0001
1273 (82.3) 1207 (78.0) 1193 (77.3) 1179 (76.0) 0.0001
422 (27.3) 538 (34.8) 660 (42.7) 736 (47.5) 0.0001
359 (23.2) 335 (21.7) 332 (21.5) 296 (19.1) 0.0456
296 (19.1) 299 (19.3) 293 (19.0) 328 (21.1) 0.3901
597 (38.6) 546 (35.3) 485 (31.4) 397 (25.6) 0.0001
556 (35.9) 548 (35.4) 537 (34.8) 556 (35.8)
394 (25.5) 453 (29.3) 522 (33.8) 598 (38.6)
190 (12.3) 214 (13.8) 296 (19.2) 378 (24.4) 0.0001
315 (20.4) 354 (22.9) 414 (26.8) 457 (29.5) 0.0001
76.4 (61.1, 93.9) 73.2 (57.8, 91.1) 68.3 (54.6, 85.2) 59.0 (46.1, 74.8) 0.0001
587 (37.9) 519 (33.5) 531 (34.4) 577 (37.2) 0.0272
922 (59.6) 968 (62.6) 1070 (69.3) 1142 (73.6) 0.0001
1053 (68.1) 1067 (69.0) 1059 (68.6) 1134 (73.1) 0.0081
704 (45.5) 667 (43.1) 668 (43.3) 631 (40.7) 0.0613
278 (18.0) 173 (11.2) 122 (7.9) 127 (8.2) 0.0001
Hijazi et al Cardiac Biomarkers in Atrial Fibrillation 1609
-
7/31/2019 Biomarcadores Que Incrementan Riesgo de Ictus en FA
6/12
cardiovascular disease (prior stroke, prevalent congestive
heart failure, and/or coronary artery disease) versus no
cardiovascular disease, yielded similar results as in the total
material with no significant interactions (data not shown).
Predictive Ability of Cardiac Biomarkers in AFfor Thromboembolic EventsIn this cohort the C-statistic for stroke and systemic embolism
was 0.605 for troponin I, 0.598 for NT-proBNP, and 0.631
when combining the cardiac biomarkers (Table 3). A model
based on the CHADS2 score (model B) yielded a C-statistic
of 0.614. The separate addition of each cardiac biomarker
improved the predictive model significantly, and even further
when adding both cardiac biomarkers to a model simulta-
neously (Table 3). The IDI was significant for all models
when adding cardiac biomarkers, separately or combined,
with relative IDI ranging from 24% to 124% depending on
the model.
For the composite thromboembolic end point, theC-statistic was 0.639 for troponin I, 0.636 for NT-proBNP,
and 0.676 when combining troponin I and NT-proBNP (Table
3). A model based on the CHADS2 score yielded a C-statistic
of 0.590. The separate addition of a cardiac biomarker
improved the predictive model significantly, and even further
when adding both cardiac biomarkers simultaneously to the
model (Table 3). The IDI was significant for all models whenadding cardiac biomarkers, separately or combined, with
relative IDI ranging from 41% to 425% depending on the
model.
The improvements in C-statistic and IDI in relation to the
CHA2DS2-VASc score (model C) were similar to the im-
provements with the CHADS2 score (model B) (Table 3).
DiscussionThe present RE-LY substudy demonstrated a high prevalence
of detectable and elevated troponin I and considerably ele-
vated NT-proBNP in patients with nonvalvular AF and a
raised risk of stroke. The degree of troponin I and NT-proBNP elevations were both independently related to a
CumulativeHazardRate
0.00
0.01
0.02
0.03
0.04
0.05
0.06
0.07
Months
0 6 12 18 24 30
Numbers at Risk
266320061023497
26391969989476
25981925958459
23821711835411
17151269593286
701543212117
0.040 g/L
0.020-0.039 g/L
0.010-0.019 g/L
-
7/31/2019 Biomarcadores Que Incrementan Riesgo de Ictus en FA
7/12
Table 2. Cox Proportional Hazards Model With Troponin I and NT-proBNP at Randomization in Relation to Outcomes
Outcome Biomarkers Group
Total Number of
Events, n (%/y) HR (95% CI)
P Value Effect of
Biomarker Level
Addition of Cardiac
Biomarker* HR (95% CI)
P Value Effect of
Biomarker Level
Stroke and systemic
embolism
Troponin I group
(g/L)
0.010 48 (0.84) 0.0040 0.0232
0.0100.019 73 (1.72) 1.79 (1.232.59) 1.71 (1.182.48)
0.0200.039 41 (1.99) 1.97 (1.283.04) 1.76 (1.132.73)
0.040 21 (2.09) 1.99 (1.173.39) 1.68 (0.972.89)
NT-proBNP quartile
group (ng/L)
387 30 (0.92) 0.0014 0.0112
387800 40 (1.22) 1.35 (0.802.27) 1.29 (0.762.17)
8011402 40 (1.22) 1.31 (0.762.27) 1.21 (0.702.09)
1402 73 (2.30) 2.40 (1.414.07) 2.09 (1.223.58)
Vascular death Troponin I group
(g/L)
0.010 59 (1.04) 0.0001 0.0001
0.0100.019 102 (2.40) 1.94 (1.402.69) 1.75 (1.262.42)
0.0200.039 70 (3.39) 2.31 (1.613.30) 1.88 (1.312.70)
0.040 66 (6.56) 4.38 (3.056.29) 3.20 (2.204.65)
NT-proBNP quartile
group (ng/L)
387 20 (0.61) 0.0001 0.0001
387800 46 (1.40) 2.44 (1.404.27) 2.23 (1.273.89)
8011402 72 (2.19) 3.71 (2.156.41) 3.19 (1.855.52)
1402 159 (5.00) 6.73 (3.9511.49) 5.07 (2.958.71)
Nonvascular death Troponin I group(g/L)
0.010 49 (0.86) 0.0127 0.01500.0100.019 52 (1.22) 1.19 (0.801.77) 1.18 (0.791.75)
0.0200.039 42 (2.04) 1.92 (1.252.93) 1.87 (1.212.88)
0.040 10 (0.99) 0.89 (0.451.77) 0.83 (0.411.67)
NT-proBNP quartile
group (ng/L)
387 27 (0.83) 0.0767 0.0862
387800 42 (1.28) 1.31 (0.762.24) 1.25 (0.732.14)
8011402 27 (0.82) 0.79 (0.431.45) 0.73 (0.401.34)
1402 57 (1.79) 1.42 (0.802.50) 1.30 (0.732.30)
Myocardial infarction Troponin I group
(g/L)
0.010 28 (0.49) 0.0052 0.0122
0.0100.019 37 (0.87) 1.59 (0.972.62) 1.56 (0.952.57)
0.0200.039 21 (1.02) 1.77 (0.993.17) 1.72 (0.953.09)
0.040 17 (1.69) 3.04 (1.645.64) 2.88 (1.535.42)
NT-proBNP quartile
group (ng/L)
387 21 (0.64) 0.2383 0.4499
387800 28 (0.85) 1.72 (0.933.18) 1.62 (0.883.00)
8011402 24 (0.73) 1.49 (0.762.91) 1.31 (0.662.56)
1402 30 (0.94) 1.93 (0.983.82) 1.53 (0.763.08)
Composite thromboembolic
outcome
Troponin I group
(g/L)
0.010 114 (2.00) 0.0001 0.0001
0.0100.019 167 (3.93) 1.73 (1.362.21) 1.63 (1.282.08)
0.0200.039 112 (5.43) 2.11 (1.612.76) 1.83 (1.392.41)
0.040 89 (8.85) 3.43 (2.574.56) 2.77 (2.063.72)
NT-proBNP quartile
group (ng/L)
387 58 (1.78) 0.0001 0.0001
387800 97 (2.95) 1.78 (1.262.53) 1.66 (1.172.36)
8011402 112 (3.40) 2.06 (1.442.94) 1.81 (1.262.58)
1402 215 (6.76) 3.55 (2.515.02) 2.79 (1.963.98)
Major bleed Troponin I group
(g/L)
0.010 98 (1.72) 0.0009 0.0040
0.0100.019 125 (2.94) 1.48 (1.131.93) 1.45 (1.111.90)
0.0200.039 67 (3.25) 1.50 (1.092.07) 1.45 (1.052.01)
0.040 44 (4.38) 2.01 (1.392.90) 1.89 (1.302.75)
NT-proBNP quartile
group (ng/L)
387 66 (2.03) 0.1503 0.5272
387800 74 (2.25) 1.12 (0.781.62) 1.07 (0.741.54)
8011402 80 (2.43) 1.16 (0.791.70) 1.07 (0.731.57)
1402 114 (3.58) 1.47 (1.012.15) 1.28 (0.871.88)
Six thousand ninety-two patients had values for all covariates and were included in the Cox regressions. Numbers of patients in each group were as follows: troponin
I group 12663, group 22006, group 31023, and group 4497. For NT-proBNP; Q11547, Q21547, Q31544, and Q41551. NT-proBNP indicates
N-terminal pro-B-type natriuretic peptide; and HR, hazard ratio.
*Adding NT-proBNP to multivariable analysis of troponin I, and troponin I to multivariable analysis of NT-proBNP, respectively.
Stroke, systemic embolism, pulmonary embolism, myocardial infarction, vascular death (excluding hemorrhagic death).
Hijazi et al Cardiac Biomarkers in Atrial Fibrillation 1611
-
7/31/2019 Biomarcadores Que Incrementan Riesgo de Ictus en FA
8/12
raised risk of stroke or systemic embolism, mortality, and
other cardiovascular events. The levels of these biomarkers
added prognostic information beyond currently used clinical
risk scores, eg, the CHADS2 or CHA2DS2-VASc risk scores.
Elevation of troponin was initially identified as a sensitive
indicator of myocardial damage and myocardial infarction
and also as an indicator of raised risk of reinfarction and
mortality in patients with acute coronary syndromes.5,6,22 At a
later stage, slight elevations of troponin were observed in a
proportion of patients with stable coronary artery disease and
also associated with a worse outcome.8 In advanced heart
failure, elevated troponin is associated with progressive left
ventricular dysfunction and increased mortality.9 Recently,
more sensitive assays have identified detectable troponin
levels also in elderly healthy men, predicting coronary heart
disease events and mortality independent of conventional
major coronary risk factors.12
The prognostic value of natriuretic peptides has previouslybeen established for a variety of cardiovascular diseases.
Even in community-based populations without heart failure,
natriuretic peptide levels predict risk of death and cardiovas-
cular events.11,23 BNP and NT-proBNP are also prognostic of
short- and long-term mortality in patients with acute coronary
syndromes24,25 and stable coronary artery disease.7 Elevated
levels of BNP also provide prognostic information in acute
decompensated heart failure26 and in chronic heart failure.10
The simultaneous use of both cardiac biomarkers has dis-
played even further improvements in risk stratification in
patients with acute coronary syndromes.27 Our findings in the
present RE-LY substudy extend these observations to a novel
population by demonstrating the prognostic importance of
troponin I and NT-proBNP in patients with AF.
At present, risk stratification in AF is based on clinical
variables, with the CHADS2 risk score being the most widely
used. Although easy to apply, all clinical risk scores including
the novel CHA2DS2-VASc score have, at best, only a modest
discriminating ability for the individual patients, in this respectnot very different from CHADS2 risk score, with C-statistics in
CumulativeHazardRate
0.00
0.05
0.10
0.15
0.20
Months
0 6 12 18 24 30
Numbers at Risk
266320061023497
26481985994480
26181947
970464
24071736853420
17381292612291
714558217120
0.040 g/L
0.020-0.039 g/L
0.010-0.019 g/L
-
7/31/2019 Biomarcadores Que Incrementan Riesgo de Ictus en FA
9/12
the range from 0.54 to 0.65.28 We demonstrated the additive
value of troponin I and NT-proBNP to CHADS2 score by
stratifying the RE-LY biomarker cohort based on cardiac bio-
markers and CHADS2 score (Figure 3A). Within every
CHADS2 score stratum, there was also a further gradation of
thromboembolic risk in relation to the troponin I and NT-
proBNP levels. Even in low-risk patients with a CHADS2 score
of 0 to 1, any increase in troponin I (0.020 g/L) doubled the
risk, and highly elevated troponin I levels (0.040 g/L) raised
the risk 5-fold, surpassing the annual risk of patients with a
CHADS2 score of 2 and undetectable troponin I levels. The
incremental information from NT-proBNP levels was similar,
with a 2.5-fold increase in risk when comparing patients with
the highest and lowest quartiles of NT-proBNP within the group
of patients with CHADS2 score of 0 to 1 (Figure 3B). The
significantly improved C-statistics and IDI support the improve-
ment of risk prediction of thromboembolic events when adding
cardiac biomarkers to the CHADS2 and the CHA2DS2-VASc
risk scores.
A CHADS2 score 2 is currently the generally accepted
indication for treatment with oral anticoagulants in AF
patients.29 Therefore, it is noteworthy that, in the present
population, a group with low CHADS2 score of 0 to 1 andelevated levels of any or both of these cardiac biomarkers had
a higher annual rate of a composite of thromboembolic events
than patients with higher CHADS2 scores and undetectable
troponin I and/or low NT-proBNP levels. Conversely, pa-
tients without elevated cardiac biomarkers might have sub-
stantially lower risk than perceived by the CHADS2 score.
Similar findings were shown in relation to the novel
CHA2DS2-VASc risk score. Patients with high CHADS2 or
CHA2DS2-VASc risk score and elevated cardiac biomarkers
remain at high risk for thromboembolic events despite pre-
ventive treatment with effective oral anticoagulants. Such
patients might be considered for intensified pharmacological
treatment with angiotensin-converting enzyme inhibitors, an-
giotensin receptor blockers or statins, ablation therapy, left
atrial appendage closure devices, left atrial volume reduction,
and, perhaps, also myocardial perfusion stress test or coro-
nary angiogram for further risk stratification and potential
percutaneous coronary interventions.
The results of this study also document an association
between elevated troponin I levels and risk of major bleeding.
In AF, several of the variables in scores for estimating stroke
risk are the same components used for assessing bleeding
risk.30 There are some previous studies in acute coronary
syndrome populations linking peak troponin I levels tosubsequent increase of bleeding rate.31 The causality is
Figure 3. Stroke, systemic embolism, pulmonary embolism, myocardial infarction, vascular death (excluding hemorrhagic death) in rela-tion to troponin I levels and CHADS2 scores (A), NT-proBNP levels and CHADS2-scores (B), and troponin I and NT-proBNP levels (C).Total number of patients given in each bar.
Hijazi et al Cardiac Biomarkers in Atrial Fibrillation 1613
-
7/31/2019 Biomarcadores Que Incrementan Riesgo de Ictus en FA
10/12
unknown, but elevated troponin I levels might contribute to
the identification of a more fragile AF subpopulation more
likely to bleed during anticoagulation. The NT-proBNP levelswere not related to major bleeding risk in the present analysis.
The mechanism for the prognostic value of elevated troponin
I levels in patients with AF can currently only be an area for
speculation. In acute coronary syndrome, troponin levels reflect
necrosis of myocytes as a consequence of myocardial ischemia.
In patients with chronic heart failure, stable coronary disease,
apparently healthy elderly individuals, or as in this cohort of
stable AF patients, there might be alternative explanations such
as the increased ventricular rate that might lead to oxygen
demand/mismatch and myocardial ischemia, volume and pres-
sure overload, changes in microvascular blood flow, atrial
calcium overload, oxidative stress, or alterations in tissue struc-
ture.29,32,33 The pathogenesis of thrombi in AF involves poorly
contractile atrium,34 hypercoagulable state,35 and endothelial
dysfunction.36 Troponin release in AF patients may be con-
nected to several of these mechanisms associated with myocar-
dial dysfunction, apoptosis, inflammation, and fibrosis in the
atrial and ventricular musculature, as well. The higher proportion
of patients with troponin elevation in permanent AF as an
indicator of increased AF burden and a more advanced cardiac
disease supports this hypothesis and also the relation to major
bleeding events.
The mechanism for the prognostic value of elevated
NT-proBNP levels in AF seems easier to understand. Ele-
vated natriuretic peptides reflect the myocyte response toincreased wall tension. This is usually seen in settings of left
ventricular systolic or diastolic dysfunction, ventricular hy-
pertrophy,37 increasing age, and female sex.38 An acute
coronary syndrome, renal dysfunction, and high-output statesmay cause elevation of NT-proBNP as well.39 Concerning
natriuretic peptides in AF, NT-proBNP level is a predictor of
future development of AF, independent of other risk factors,
including echocardiographic parameters in older adults.40 In
accordance with the present results, the levels of NT-proBNP
have previously been shown to be elevated in patients with
AF, either with or without structural heart disease in compar-
ison with matched controls in sinus rhythm.41 After restora-
tion of sinus rhythm, either by cardioversion or ablation
therapy, the level of natriuretic peptides falls rapidly.42,43
Therefore, there are arguments for NT-proBNP being of atrial
origin in AF,44 in contrast to the pathophysiology of heart
failure, where it is derived mainly from the ventricles.45 Some
studies support this by indicating that atrial stretch is a source
of BNP in patients with AF.46 The level of natriuretic peptides
in AF may therefore, to some extent reflect, atrial dysfunc-
tion, which is an established marker of atrial thrombus
formation,34 and thereby provide a plausible mechanism for
the prognostic importance of elevated NT-proBNP levels and
thromboembolic events as shown in the present study.
There are several limitations of this study. The findings
concern a population with nonvalvular AF with at least 1 risk
factor for stroke. To extend and apply the results to AF
patients without any clinical stroke risk factors, further
studies in other AF populations are warranted. Furthermore,the study design, with all study participants receiving oral
Table 3. Receiver Operating Characteristics for Stroke or Systemic Embolism, and the Composite of Stroke, Systemic Embolism,
Pulmonary Embolism, Myocardial Infarction, Vascular Death (Excluding Hemorrhagic Death)
Model
Stroke and Systemic Embolism Composite Thromboembolic Outcome*
C-statistic P Value IDI Relative IDI, % C-statistic P Value IDI Relative IDI, %
Troponin I 0.605 Referent 0.640 Referent
NT-proBNP 0.598 0.640
Troponin INT-proBNP 0.631 0.0228 0.0027 67 0.676 0.0001 0.0126 57
CHADS2 0.614 Referent 0.596 Referent
Troponin I 0.646 0.0398 0.0033 70 0.667 0.0001 0.0200 239
NT-proBNP 0.637 0.1157 0.0036 76 0.662 0.0001 0.0177 211
Troponin INT-proBNP 0.658 0.0141 0.0059 124 0.691 0.0001 0.0355 425
CHA2DS2-VASc 0.618 Referent 0.612 Referent
Troponin I 0.647 0.0492 0.0033 59 0.674 0.0001 0.0195 152
NT-proBNP 0.633 0.2393 0.0035 63 0.668 0.0001 0.0160 125
Troponin INT-proBNP 0.654 0.0279 0.0058 103 0.696 0.0001 0.0295 230
CV risk factors 0.679 Referent 0.679 Referent
Troponin I 0.690 0.2620 0.0032 24 0.703 0.0007 0.0165 49
NT-proBNP 0.692 0.1486 0.0041 30 0.707 0.0001 0.0136 40
Troponin INT-proBNP 0.700 0.0641 0.0064 47 0.720 0.0001 0.0247 73
NT-proBNP indicates N-terminal pro-B-type natriuretic peptide; IDI, integrated discrimination improvement; CV, cardiovascular; AF, atrial fibrillation; TIA, transient
ischemic attack.
*Stroke, systemic embolism, pulmonary embolism, myocardial infarction, vascular death (excl hemorrhagic death).
All P0.01.
CVs risk factors: Adjusted for study treatment, use of (prestudy) anticoagulant treatment at randomization and established risk factors for cardiovascular disease,
ie, age, sex, body mass index, smoking status, sitting systolic blood pressure, sitting heart rate, AF duration, AF type, creatinine clearance, diabetes, coronary artery
disease, previous stroke/systemic embolism/TIA, heart failure, hypertension, treatment at randomization with aspirin, angiotensin-converting enzyme inhibitors or
angiotensin II receptor blockers, and statins.
1614 Circulation April 3, 2012
-
7/31/2019 Biomarcadores Que Incrementan Riesgo de Ictus en FA
11/12
anticoagulants, does not allow final conclusions concerning
the optimal cutoff value of cardiac biomarkers as a decision-
support tool for improved selections of AF patients for oral
anticoagulation. The mechanisms behind the release and
origin of NT-proBNP in AF patients without congestive
heart failure need further clarification, and the exact
mechanisms behind troponin elevations and their relations
to events such as stroke and bleeding in AF, as well.
Although the current troponin I assay has shown robust
analytic performance in patients who have coronary artery
disease and are older,12,14 newly developed assays with
even higher sensitivity and precision might provide even
better identification of patients at increased risk and with a
potential benefit of oral anticoagulation.
ConclusionElevated levels of troponin I and NT-proBNP are common in
patients with AF and at least 1 risk factor for stroke and
associated with an increase in the risk for stroke or systemic
embolism and vascular events. The prognostic informationfrom the troponin I and NT-proBNP levels are independent of
and additive to established clinical risk factors such as the
CHADS2 and CHA2DS2-VASc risk scores.
Source of FundingThe RE-LY trial w as funded by Boehringer IngelheimPharmaceuticals.
DisclosuresAll authors have completed and submitted the ICMJE Form forDisclosure of Potential Conflicts of Interest. Dr Hijazi reports receivinglecture fees and an institutional research grant from Boehringer-Ingelheim. Dr Oldgren reports receiving consulting and lecture fees, and
grant support from Boehringer Ingelheim, and consultant and lecturefees from Bayer and Bristol-Myers Squibb. Ms Andersson reports noconflicts of interest. Dr Connolly reports receiving consulting fees,lecture fees, and grant support from Boehringer Ingelheim. Dr Ezekow-itz reports receiving consulting fees, lecture fees, and grant support fromBoehringer Ingelheim and Aryx Therapeutics; consulting fees fromSanofi-aventis; and lecture fees and grant support from Portola Phar-maceuticals. Dr Hohnloser reports receiving consulting fees and lecturefees from Boehringer Ingelheim, St. Jude Medical, and Sanofi-aventis,and lecture fees from Cardiome. Dr Reilly is an employee of BoehringerIngelheim. Dr Vinereanu reports receiving lecture fees and grant supportfrom Boehringer Ingelheim. Dr Siegbahn reports consulting fees, lecturefees, and grant support from Boehringer Ingelheim; lecture fees andgrants from Eli Lilly; and grant support from AstraZeneca. Dr Yusufreports receiving consulting fees, lecture fees, and grant support fromBoehringer Ingelheim; and consulting fees from AstraZeneca, Bristol-Myers Squibb, and Sanofi-aventis. Dr Wallentin reports receivingconsulting and lecture fees, honoraria, and research grants from Boeh-ringer Ingelheim; research grants from AstraZeneca, Bristol-MyersSquibb, GlaxoSmithKline, and Schering-Plough; honoraria from Astra-Zeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, andSchering-Plough; consultant fees from Athera Biotechnologies, Astra-Zeneca, Eli Lilly, GlaxoSmithKline, and Regado Biotechnologies; andlecture fees from AstraZeneca and Eli Lilly.
References1. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer
DE. Prevalence of diagnosed atrial fibrillation in adults: National impli-
cations for rhythm management and stroke prevention: the anticoagu-
lation and risk factors in atrial fibrillation (atria) study. JAMA. 2001;285:
23702375.
2. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independentrisk factor for stroke: The Framingham Study. Stroke. 1991;22:983988.
3. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford
MJ. Validation of clinical classification schemes for predicting stroke:
results from the national registry of atrial fibrillation. JAMA. 2001;285:
28642870.
4. Boomsma F, van den Meiracker AH. Plasma a- and b-type natriuretic
peptides: physiology, methodology and clinical use. Cardiovasc Res.
2001;51:442449.
5. James SK, Armstrong P, Barnathan E, Califf R, Lindahl B, Siegbahn A,
Simoons ML, Topol EJ, Venge P, Wallentin L. Troponin and c-reactiveprotein have different relations to subsequent mortality and myocardial
infarction after acute coronary syndrome: a GUSTO-IV substudy. J Am
Coll Cardiol. 2003;41:916924.
6. Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of
myocardial damage and inflammation in relation to long-term mortality in
unstable coronary artery disease. FRISC study group. Fragmin during
instability in coronary artery disease. N E ngl J M ed. 2000;343:
11391147.
7. Kragelund C, Grnning B, Kber L, Hildebrandt P, Steffensen R.
N-terminal pro-B-type natriuretic peptide and long-term mortality in
stable coronary heart disease. N Engl J Med. 2005;352:666675.
8. Omland T, de Lemos JA, Sabatine MS, Christophi CA, Rice MM,
Jablonski KA, Tjora S, Domanski MJ, Gersh BJ, Rouleau JL, Pfeffer MA,
Braunwald E. A sensitive cardiac troponin T assay in stable coronary
artery disease. N Engl J Med. 2009;361:25382547.
9. Horwich TB, Patel J, MacLellan WR, Fonarow GC. Cardiac troponin
I is associated with impaired hemodynamics, progressive left ventric-
ular dysfunction, and increased mortality rates in advanced heart
failure. Circulation. 2003;108:833838.
10. Tsutamoto T, Wada A, Maeda K, Hisanaga T, Maeda Y, Fukai D,
Ohnishi M, Sugimoto Y, Kinoshita M. Attenuation of compensation of
endogenous cardiac natriuretic peptide system in chronic heart failure:
prognostic role of plasma brain natriuretic peptide concentration in
patients with chronic symptomatic left ventricular dysfunction.
Circulation. 1997;96:509516.
11. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, Wolf
PA, Vasan RS. Plasma natriuretic peptide levels and the risk of cardio-
vascular events and death. N Engl J Med. 2004;350:655 663.
12. Zethelius B, Johnston N, Venge P. Troponin I as a predictor of coronary
heart disease and mortality in 70-year-old men: a community-based
cohort study. Circulation. 2006;113:10711078.
13. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A,
Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier
D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin
L. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl
J Med. 2009;361:11391151.
14. Eggers KM, Lagerqvist B, Venge P, Wallentin L, Lindahl B. Persistent
cardiac troponin I elevation in stabilized patients after an episode of acute
coronary syndrome predicts long-term mortality. Circulation. 2007;116:
19071914.
15. Uettwiller-Geiger D, Wu AH, Apple FS, Jevans AW, Venge P, Olson
MD, Darte C, Woodrum DL, Roberts S, Chan S. Multicenter evaluation
of an automated assay for troponin I. Clini Chem. 2002;48:869876.
16. Johnston N, Jernberg T, Lindahl B, Lindback J, Stridsberg M, Larsson A,
Venge P, Wallentin L. Biochemical indicators of cardiac and renal
function in a healthy elderly population. Clin Biochem. 2004;37:
210216.
17. Yeo KT, Wu AH, Apple FS, Kroll MH, Christenson RH, Lewandrowski
KB, Sedor FA, Butch AW. Multicenter evaluation of the RocheNT-proBNP assay and comparison to the Biosite Triage BNP assay. Clin
Chim Acta. 2003;338:107115.
18. Venge P, Lagerqvist B, Diderholm E, Lindahl B, Wallentin L. Clinical
performance of three cardiac troponin assays in patients with unstable
coronary artery disease (a FRISC II substudy). Am J Cardiol. 2002;89:
10351041.
19. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas
under two or more correlated receiver operating characteristic curves: a
nonparametric approach. Biometrics. 1988;44:837845.
20. Pencina MJ, DAgostino RB Sr, DAgostino RB Jr, Vasan RS. Evaluating
the added predictive ability of a new marker: from area under the ROC
curve to reclassification and beyond. Stat Med. 2008;27:157172.
21. Pencina MJ, DAgostino RB Sr, DAgostino RB Jr, Vasan RS. Comments
on integrated discrimination and net reclassification improvements
practical advice. Stat Med. 2008;27:207212.
22. Antman EM, Tanasijevic MJ, Thompson B, Schactman M, McCabe CH,Cannon CP, Fischer GA, Fung AY, Thompson C, Wybenga D,
Hijazi et al Cardiac Biomarkers in Atrial Fibrillation 1615
-
7/31/2019 Biomarcadores Que Incrementan Riesgo de Ictus en FA
12/12
Braunwald E. Cardiac-specific troponin I levels to predict the risk of
mortality in patients with acute coronary syndromes. N Engl J Med.
1996;335:13421349.
23. Zethelius B, Berglund L, Sundstrom J, Ingelsson E, Basu S, Larsson A,
Venge P, Arnlov J. Use of multiple biomarkers to improve the prediction
of death from cardiovascular causes. N Engl J Med. 2008;358:21072116.
24. de Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS,
McCabe CH, Hall C, Cannon CP, Braunwald E. The prognostic value of
B-type natriuretic peptide in patients with acute coronary syndromes.
N Engl J Med. 2001;345:10141021.
25. James SK, Lindahl B, Siegbahn A, Stridsberg M, Venge P, Armstrong P,
Barnathan ES, Califf R, Topol EJ, Simoons ML, Wallentin L. N-terminal
pro-brain natriuretic peptide and other risk markers for the separate
prediction of mortality and subsequent myocardial infarction in patients
with unstable coronary artery disease: a Global Utilization of strategies
To Open occluded arteries (GUSTO)-IV substudy. Circulation. 2003;
108:275281.
26. Fonarow GC, Peacock WF, Phillips CO, Givertz MM, Lopatin M.
Admission B-type natriuretic peptide levels and in-hospital mortality in
acute decompensated heart failure. J Am Coll Cardiol. 2007;49:
19431950.
27. Sabatine MS, Morrow DA, de Lemos JA, Gibson CM, Murphy SA, Rifai
N, McCabe C, Antman EM, Cannon CP, Braunwald E. Multimarker
approach to risk stratification in non-ST elevation acute coronary syn-
dromes: simultaneous assessment of troponin I, C-reactive protein, and
B-type natriuretic peptide. Circulation. 2002;105:17601763.
28. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical
risk stratification for predicting stroke and thromboembolism in atrial
fibrillation using a novel risk factor-based approach: the euro heart survey
on atrial fibrillation. Chest. 2010;137:263272.
29. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van
Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri
O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A,
Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski
P, Rutten FH, Vahanian A, Auricchio A, Bax J, Ceconi C, Dean V,
Filippatos G, Funck-Brentano C, Hobbs R, Kearney P, McDonagh T,
Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Vardas PE,
Widimsky P, Agladze V, Aliot E, Balabanski T, Blomstrom-Lundqvist C,
Capucci A, Crijns H, Dahlof B, Folliguet T, Glikson M, Goethals M,
Gulba DC, Ho SY, Klautz RJ, Kose S, McMurray J, Perrone Filardi P,
Raatikainen P, Salvador MJ, Schalij MJ, Shpektor A, Sousa J, Stepinska
J, Uuetoa H, Zamorano JL, Zupan I. Guidelines for the management ofatrial fibrillation: the task force for the management of atrial fibrillation
of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:
23692429.
30. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel
user-friendly score (HAS-BLED) to assess one-year risk of major
bleeding in atrial fibrillation patients: The Euro Heart Survey. Chest.
2010:10931100.
31. Al-Mallah M, Bazari RN, Jankowski M, Hudson MP. Predictors and
outcomes associated with gastrointestinal bleeding in patients with acute
coronary syndromes. J Thromb Thrombolysis. 2007;23:5155.
32. Eggers KM, Lind L, Ahlstrom H, Bjerner T, Ebeling Barbier C, Larsson
A, Venge P, Lindahl B. Prevalence and pathophysiological mechanisms
of elevated cardiac troponin I levels in a population-based sample of
elderly subjects. Eur Heart J. 2008;29:22522258.
33. Jeremias A, Gibson CM. Narrative review: alternative causes for elevated
cardiac troponin levels when acute coronary syndromes are excluded. Ann
Intern Med. 2005;142:786791.
34. The Stroke Prevention in Atrial Fibrillation Investigators Committee on
Echocardiography. Transesophageal echocardiographic correlates of
thromboembolism in high-risk patients with nonvalvular atrial fibril-
lation. The stroke prevention in atrial fibrillation investigators committeeon echocardiography. Ann Intern Med. 1998;128:639647.
35. Asakura H, Hifumi S, Jokaji H, Saito M, Kumabashiri I, Uotani C,
Morishita E, Yamazaki M, Shibata K, Mizuhashi K. Prothrombin
fragment F1 2 and thrombin-antithrombin III complex are useful
markers of the hypercoagulable state in atrial fibrillation. Blood Coagul
Fibrinolysis. 1992;3:469473.
36. Conway DS, Pearce LA, Chin BS, Hart RG, Lip GY. Plasma von
Willebrand factor and soluble p-selectin as indices of endothelial
damage and platelet activation in 1321 patients with nonvalvular atrial
fibrillation: relationship to stroke risk factors. Circulation. 2002;106:
19621967.
37. Braunwald E. Biomarkers in heart failure. N Engl J Med. 2008;358:
21482159.
38. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR,
Burnett JC Jr. Plasma brain natriuretic peptide concentration: impact of
age and gender. J Am Coll Cardiol. 2002;40:976982.39. Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol. 2007;
50:23572368.
40. Patton KK, Ellinor PT, Heckbert SR, Christenson RH, DeFilippi C,
Gottdiener JS, Kronmal RA. N-terminal pro-B-type natriuretic peptide is
a major predictor of the development of atrial fibrillation: the Cardio-
vascular Health Study. Circulation. 2009;120:17681774.
41. Shelton RJ, Clark AL, Goode K, Rigby AS, Cleland JG. The diagnostic
utility of N-terminal pro-B-type natriuretic peptide for the detection of
major structural heart disease in patients with atrial fibrillation. Eur
Heart J. 2006;27:23532361.
42. Wozakowska-Kaplon B. Effect of sinus rhythm restoration on plasma
brain natriuretic peptide in patients with atrial fibrillation. Am J Cardiol.
2004;93:15551558.
43. Yamada T, Murakami Y, Okada T, Okamoto M, Shimizu T, Toyama J,
Yoshida Y, Tsuboi N, Ito T, Muto M, Kondo T, Inden Y, Hirai M,
Murohara T. Plasma atrial natriuretic peptide and brain natriuretic peptidelevels after radiofrequency catheter ablation of atrial fibrillation. Am J
Cardiol. 2006;97:17411744.
44. Goetze JP, Friis-Hansen L, Rehfeld JF, Nilsson B, Svendsen JH. Atrial
secretion of B-type natriuretic peptide. Eur Heart J. 2006;27:16481650.
45. Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K, Jougasaki M,
Ogawa H, Okumura K, Mukoyama M, Nakao K. Localization and
mechanism of secretion of B-type natriuretic peptide in comparison with
those of A-type natriuretic peptide in normal subjects and patients with
heart failure. Circulation. 1994;90:195203.
46. Inoue S, Murakami Y, Sano K, Katoh H, Shimada T. Atrium as a source
of brain natriuretic polypeptide in patients with atrial fibrillation. J Card
Fail. 2000;6:9296.
CLINICAL PERSPECTIVETroponin I and N-terminal pro-B-type natriuretic peptide (NT-proBNP) are widely available biomarker analyses for
diagnosis and prognostication of cardiac diseases. We demonstrated that elevated levels of troponin I and NT-proBNP were
common in patients with atrial fibrillation, with troponin elevations observed in 25% of the patients and NT-proBNP
elevations in almost 75% of the patients. Elevated levels of any or both of these cardiac biomarkers provided incremental
prognostic information to the currently used CHADS2 and CHA2DS2-VASc risk scores. Beyond clinical risk factors, an
elevated level of troponin I or NT-proBNP identifies patients with a doubled risk for stroke or systemic embolism, and up
to 6-fold increased risk of vascular death. Determination of troponin I or NT-proBNP may be used to improve risk
prediction in patients with atrial fibrillation beyond currently used clinical risk scores.
1616 Circulation April 3, 2012